Adalyon’s CEO, Ulrik Zeuthen, notes that speech-based biomarkers can be used across several applications to optimise trial ...

Atea showcased its Phase III HCV programme at JPM, positioning the regimen for test-and-treat adoption in 1,800 patients.

Intellia Therapeutics CEO John Leonard explained the circumstances of the patient death at the J.P. Morgan Healthcare ...

Axsome Therapeutics has initiated the FORWARD Phase III trial evaluating AXS-14 for the management of fibromyalgia, with the ...

Sanofi's amlitelimab has shown promise in the Phase III COAST 1 trial, but data from the COAST 2 study is yet to be announced ...

The UK has announced new clinical trial regulatory reforms to boost its appeal as a leading destination for medical research.

The FDA and EMA's joint guidance was created to ensure the pharmaceutical industry employs best practices when using AI in ...

GSK will be filing for approval of bepirovirsen in hepatitis B to global regulatory authorities based on the Phase III data.

Clinical and commercial quality controls are eased as the FDA looks to expedite therapy approvals in areas of unmet need.

Anktiva plus checkpoint inhibitor therapy demonstrated statistically significant immune restoration across two clinical ...

NRG Therapeutics has dosed the first participants in its Phase I clinical trial of NRG5051, being developed as a ...

In a paper published in Nature Scientific Reports, the UK Biobank was used to better understand how the risk of stroke is ...